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Abstract: The Gram-positive bacterium Staphylococcus aureus is one of the most frequent 
pathogens that causes severe morbidity and mortality throughout the world. S. aureus can 
infect skin and soft tissues or become invasive leading to diseases such as pneumonia, 
endocarditis, sepsis or toxic shock syndrome. In contrast, S. aureus is also a common 
commensal microbe and is often part of the human nasal microbiome without causing any 
apparent disease. In this review, we explore the immunomodulation and disease tolerance 
mechanisms that promote commensalism to S. aureus. 




Staphylococcus aureus is a Gram-positive bacterium of the Micrococcae family [1]. It has a thick cell 
wall composed of approximately 50% peptidoglycan (PGN) by weight [1]. S. aureus is commonly found 
as commensal bacteria located superficially on the human anterior nares, its primary reservoir [1,2]. 
From the nostrils, the bacteria can further spread to other sites such as the throat, skin, vagina, perineum, 
and the gastrointestinal tract [2]. 
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Although it is a commensal, S. aureus is well equipped with a variety of virulence factors such as 
microcapsules, toxins, and drug resistance genes that contribute to pathology [1]. Infections with  
S. aureus occur with a seasonal trend, being highest in the summer and lowest in the winter [3]. S. aureus 
is the primary cause of local skin and soft tissue infections (SSTI) such as impetigo, dermatitis, and 
cellulitis [1,4]. Systemic infections caused by S. aureus include bacteremia, pneumonia, osteomyelitis, 
endocarditis, sepsis, and toxic shock syndrome (TSS) [4]. Invasive diseases by S. aureus have the highest 
annual death toll for any single infectious agent in the US, with close to 20% mortality [3,4]. One reason 
for this high death toll is the presence of methicillin-resistant S. aureus (MRSA). MRSA caused an 
estimated 80, 641 infections in US during 2011. Of these infections, 78% occurred in outpatients or 
within the community and carried a mortality rate of over 10% [5]. 
At any moment in time, 30%–50% of healthy adults are colonized with S. aureus and a fewer amount 
of those (around 20%) are persistently colonized [1,2]. It can be argued that everyone at some point is a 
carrier of S. aureus since serum immunoglobulin G (IgG) antibodies against staphylococcal antigens can 
be found in the entire population despite the lack of history of S. aureus infection [6]. S. aureus carriage 
rates differ based on ethnicity, gender, and age [7]. Currently, MRSA carriage rates remain much lower 
than S. aureus carriage but are gradually increasing [7]. In addition to humans, other natural reservoirs 
of S. aureus include cattle, sheep, and goat, yet the strain lineages appear to have evolved distinctively 
in each host [8]. S. aureus is reported to have a large economic impact in the dairy industry since it is 
the primary cause of mastitis [8]. Mice are not a natural reservoir of S. aureus and display a relative 
resistance to both the bacterium and its toxins, something to keep in mind when considering mouse 
models of disease [2,9]. 
We have termed S. aureus a pathobiont [10]. This classification refers to microbes that are regularly 
safe for their host but under certain conditions, other than immunosuppression, can become pathogenic. 
The switch between commensalism and pathogenicity is an important research topic because carriers 
have a greater risk of infection with their endogenous strain [2]. Over 90% of adult atopic dermatitis 
(AD) patients have either S. aureus colonization in their nares or skin [2], and 80% of S. aureus 
bacteremia cases in carriers were caused by their endogenous strain [11]. In fact, commensal isolates 
have been shown to contain most of the virulence factors and microbe-associated molecular patterns 
(MAMPs) that correlate with disease. Remarkably, carriers of S. aureus tend to have better outcomes to 
S. aureus bacteremia than non-carriers [2,11,12]. It is hypothesized that this difference in outcomes is 
due to varying degrees of immunomodulation or “priming” during S. aureus colonization [2]. 
2. Innate and Adaptive Immune Responses to S. aureus 
2.1. Innate Immunity to S. aureus 
The uppermost layer of the skin, the corneal layer, acts as a physical barrier to the microbiota, 
including S. aureus. In addition, chemical “elements” of defense such as anti-microbial peptides  
(e.g., human β-defensins 2 and 3) are secreted to the outer layer to control bacterial growth and  
breaching [4]. Below this protective cover, multiple cutaneous layers contain cells that will act as the 
first responders to S. aureus. Phagocytic cells and keratinocytes recognize MAMPs through their 
pathogen recognition receptors (PRRs) triggering a cutaneous immune response [13]. PRRs are a class 
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of molecules that include cytosolic receptors (e.g., NOD-like receptors (NLRs), and RIG-I like receptors 
(RLRs)), secreted molecules (e.g., pentraxins and collectins) [14], and trans-membrane receptors (e.g., 
toll-like receptors (TLRs) and C-type lectin receptors (CLRs)) [13]. In the context of S. aureus 
recognition, NOD1/2 recognize muramyl dipeptides, which are PGN-derived fragments [15]. CLRs bind 
to microbial sugars in a calcium-dependent manner and further associate with other cell surface receptors 
to enhance phagocytosis [14]. TLR2 recognizes components of the bacterial cell wall such as teichoic 
acid, lipoteichoic acid (LTA), and PGN-embedded lipopeptides [15]. 
Since TLR2 has been reported as the dominant receptor for S. aureus and other Gram-positive  
bacteria [16–20], it will be the main focus of this review. TLR2 often dimerizes with either TLR1 or 
TLR6, and once engaged recruits adaptor proteins, TIRAP and MyD88, and the serine/threonine kinases 
IRAK-1 and 4 to initiate signaling [21]. Recruitment of these proteins leads to the activation of two  
pro-inflammatory pathways: NF-κB and mitogen-activated protein kinases (MAPKs) [21]. Ultimately, 
this translates into production of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α, and IL-12p70) 
and chemokines (e.g., CXCL8, CCL2, CCL3, and CCL4), which are essential in combating infection by 
facilitating and enhancing phagocytosis and inflammation [21]. 
Plasticity in TLR2 signaling has been reported depending on the cell type expressing the receptor and 
the structure of the TLR2 ligands. Recently, our group has reported the existence of two sets of MAMPs 
that can trigger either predominantly pro-inflammatory or predominantly anti-inflammatory responses 
to TLR2 signaling [22]. TLR2 signaling on monocytes and macrophages will lead to a primarily  
anti-inflammatory response characterized by IL-10 production [15]. This response is not secondary to 
an alternative activation of these cells or M2 phenotype. In contrast, TLR2 signaling on dendritic cells 
(DCs) leads to a TH1/TH17 pro-inflammatory response through the production of IL-12 and IL-23 [15]. 
At the cellular level, neutrophils are the first cells to attempt the clearance of S. aureus [23]. They 
phagocytose the bacteria and use agents such as hypochloric acid (HOCl) and oxygen radicals to destroy 
the engulfed microbe. These activated neutrophils may also release DNA into the extracellular matrix to 
produce neutrophil extra traps (NETs) that control microbial spread, and enhance the cytotoxicity of 
antimicrobial agents while limiting immunopathology. Following the uptake of bacteria, neutrophils 
typically undergo accelerated apoptosis and are cleared by macrophages through efferocytosis. This 
process results in clearance of the microbe and recovery of the inflamed tissue to homeostasis [23]. However, 
in some circumstances, S. aureus pathogenicity is enhanced by a neutrophil-rich environment [23,24]. 
Some of these mechanisms will be touched upon later in this review. 
2.2. Adaptive Immunity to S. aureus 
When innate immune mechanisms are not sufficient to clear the bacterial infection, adaptive immune 
mechanisms are activated. An adaptive immune response to S. aureus requires a mixture of TH1, TH17, 
and humoral antibody responses. For example in SSTI both cellular and humoral responses (primary or 
secondary) are observed [25]. A TH1/TH17 response is associated with the production of IL-1 and  
IL-17A to promote abscess formation at the site of infection [4]. Abscessification is the hallmark of S. 
aureus infections and is required for the clearance of bacteria via phagocytosis and oxidative burst [4]. 
The Hyper-IgE Syndrome (HIES) highlights the importance of the TH17 responses in controlling S. 
aureus infections. In this syndrome, a mutation in the stat3 gene results in lower levels of retinoid-related 
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orphan receptor (ROR) γt [26], the master regulator of TH17 lineage differentiation. Thus, these patients 
show defective IL-17A production and increased susceptibility to S. aureus infections [26]. HIES is 
manifested as a TH2 phenotype concomitant with the absence of TH17 cells [26] but it is not clear whether 
this clinical presentation is because of the lack of RORγt, IL-17A, IL-17A receptor (IL-17RA), or 
STAT3. It is known that IL-17RA deficiency leads to susceptibility to mucocutaneous Candidiasis but 
not to S. aureus [27]. In addition, a more recent publication noted that RORγt deficiency in itself results 
in susceptibility to Candida and Mycobacterium infections but not to increased susceptibility to  
S. aureus [28]. 
A TH1 response during S. aureus infections is commonly associated with TSS where staphylococcal 
superantigens (SAgs) activate roughly 20% of T cells leading to their massive proliferation and 
production of cytokines [29]. This activation occurs by the binding of the SAg to selective variable 
regions of the T cell receptor β-chain (TCR-Vβ) and to some MHC class II molecules on antigen-presenting 
cells (APCs) [29]. SAg expression is not exclusive to isolates from TSS-associated strains. In fact, the 
staphylococcal enterotoxin gene cluster (egc) containing 6 SAgs is commonly found in commensal 
isolates [29,30]. Another example is the staphylococcal enterotoxin A (SEA), which is well known for 
inducing a strong pro-inflammatory/TH1 response, and can be found in pathogenic as well as commensal 
isolates. However, this is not unique to SEA because all SAgs have been found to share similar 
superantigenicity when levels of pro-inflammatory/TH1 cytokines were measured in vitro [29]. 
In addition to T cell responses, humoral responses have been found to play a role in the outcome of 
S. aureus infections. In the serum of patients with S. aureus bacteremia, IgG antibodies targeting eight 
conserved extracellular proteins can be found. Of these targets, seven are coded by the bacterial core 
genome [6]. The proteins targeted by these antibodies include phospholipase and immunodominant 
staphylococcal protein A (IsaA) [6]. These antibodies may have prognostic value since higher affinity 
antibodies are associated to better outcomes for sepsis patients [6]. 
The role of immunological memory to S. aureus in humans is still unclear [2,31,32]. There is currently 
no clinical evidence to claim protective immune memory to S. aureus. This observation is in line with 
challenges we have in developing a vaccine against this microbe. In mice, recent studies suggest that  
IL-17A may be important for the development of a memory state because a high IL-17A-to-IFNγ ratio 
in mice has been linked to protective memory to SSTI [25]. This IL-17A-to-IFNγ ratio seems to be 
determined by the genetic background of the host [25]. This evidence would suggest that the 
development of immunological memory to S. aureus may reflect a balance between nominal  
antigen-induced TH17 responses and SAg-induced TH1 responses. If so, the former response would 
conduce to protection upon re-exposure, whereas the later would not. However, this may not be 
applicable to the same extent in humans because patients with a defect in RORγt or IL-17 receptor 
signaling, which lead to impaired TH17 responses, show no increased susceptibility to repeated  
S. aureus infections [27,28]. 
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3. Cellular Basis of Immunomodulation by S. aureus 
The capacity of a microbe to induce anti-inflammatory responses and to restrain host pro-inflammatory 
responses to that microbe is referred to as immunomodulation. In addition to triggering host innate and 
adaptive immunity, S. aureus has a plethora of sophisticated mechanisms that allow it to induce 
immunomodulation that promote disease tolerance and establish commensalism. The precise molecular 
and cellular basis of immunomodulation is starting to emerge. 
Like other microbes, recognition of S. aureus relies on MAMPs binding to PRRs on host cells. These 
cells include epithelial cells, macrophages, DCs and neutrophils [10]. PGN from Gram-positive bacteria, 
which contains teichoic acid, LTA and lipoprotein, is the main source of MAMPs. TLR2 has emerged 
as a dominant receptor for some of these molecules [4]. The qualitative and quantitative representation 
of TLR2, 1, 6 and 10, as well as the accessory molecules CD14 and CD36 on these cells, will likely 
determine the spectrum of their response [33–35]. Recognition of MAMPs by PRRs leads to a strong 
release of pro-inflammatory cytokines and chemokines, as well as the anti-inflammatory cytokine IL-10 [36]. 
Although most S. aureus isolates express at least one SAg [37–39], the incidence of TSS in S. aureus 
carriers is low [40,41]. This paradox may be explained by the fact that the staphylococcal cell wall  
down-regulates SAg-induced T cell activation. S. aureus PGN-embedded TLR2 ligands induce IL-10 
production and apoptosis of APCs, down-regulating SAg-induced T cell activation and preventing  
TSS [42]. Consistent with this mechanism, it has been reported that staphylococcal LTA is able to inhibit 
injury-induced skin inflammation through a TLR2-dependent mechanism [43]. 
In addition to cell wall components, secreted staphylococcal toxins can mediate immunomodulation 
in SSTI. In a murine model of dermonecrosis, infection with an α-toxin-deficient S. aureus strain resulted 
in enhanced innate and adaptive immune responses, compared with infection with wild-type strain, as 
illustrated by increased neutrophil infiltration, influx of innate IL-17+ γδ T cells, recruitment of TH1 and 
TH17 cells, and enhanced pro-inflammatory cytokine and chemokine production. These effects were 
correlated with reduced lesion size. The enhancement of the response to S. aureus was also observed 
with the administration of an α-toxin neutralizing antibody prior to the staphylococcal infection [44]. 
Altogether, these data suggest a role of α-toxin in immunomodulation. 
Emerging evidence suggests that IL-10 is an important mediator of immunomodulation by S. aureus. 
IL-10 inhibits TH1 and TH17 responses to S. aureus [15]. In humans, IL-10 can also inhibit TH2  
responses [45]. In addition to the effect on pro-inflammatory cytokines, IL-10 down-regulates 
production of some chemokines such as CCL3, CCL4, CXCL8, and CXCL10 [46], resulting in 
prevention of immune cell recruitment to inflammatory sites. Furthermore, IL-10 down-regulates 
expression of MHC class II [47] and co-stimulatory molecules on APCs [48,49], leading to decreased  
T cell activation. 
Quantitatively, monocytes and macrophages are the main source of IL-10 in response to S. aureus. 
The production of IL-10 by monocytes and macrophages is between 4 and 20 times higher than that by 
DCs [15]. In contrast, when DCs are the predominant APC, S. aureus triggers a robust TH1/TH17 
response [15]. This difference suggests that the capacity of immunomodulation by S. aureus is dependent 
on the type of APC. Consequently, one would expect different outcomes of S. aureus detection in 
different tissues based on different cellular composition. For example, in the nose, macrophages are the 
primary APCs, whereas in the skin Langerhans cells and other DCs are more abundant. This might 
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explain why S. aureus usually acts as a commensal in the nose (i.e., nasal carrier) and a pathogen in the 
skin (e.g., AD). 
S. aureus can also induce immunomodulation through the regulation of monocyte/macrophage 
function and differentiation. In a mouse model of catheter-associated biofilm infection, S. aureus 
attenuated phagocytosis by macrophages, and polarized these cells towards an alternatively activated 
M2 phenotype, altogether down-regulating host inflammatory responses [50]. Targeting macrophage 
activation with administration of the C5a receptor agonist EP67 or with pro-inflammatory M1 
macrophages reduced the staphylococcal bacterial burden [51]. In line with these findings, macrophages 
from chronic rhinosinusitis patients with nasal polyps show reduced capacity of S. aureus phagocytosis 
and are polarized to a M2 phenotype compared to macrophages from chronic rhinosinusitis patients 
without nasal polyps. This correlates with more staphylococcal colonization in the former patients. These 
findings suggest that alternative activation of macrophages contributes to S. aureus chronic infection 
and colonization [52]. The mechanism by which S. aureus skews macrophage differentiation has been 
linked to Akt1 signaling and subsequent regulation of the miR-155/SOCS1 axis [53]. 
In addition to monocytes and macrophages, T cells can produce IL-10 upon S. aureus infection. It is 
unlikely that S. aureus directly interacts with T cells to induce IL-10 production, since human resting T 
cells do not express TLR2 [54]. However, S. aureus can imprint T cells to produce IL-10. For example, 
it has been reported that S. aureus primes naïve T cells to differentiate into IL-10-producing TH17 cells [55]. 
In another in vitro polarization study, S. aureus imprinted neonatal cord blood CD4+ T cells to 
differentiate into FOXP3+CD25+CD127l°w Treg cells through a PD-1/PD-L1 dependent mechanism [56]. 
Induction of IL-10 production by S. aureus can also facilitate immune evasion, which under certain 
circumstances is a form of immunomodulation. IL-10 inhibits pro-inflammatory immune responses and 
establishes an anti-inflammatory environment [46,57]. Under these conditions, there is decreased 
immune cell recruitment to the infection site, which contributes to reduced pathogen elimination and 
ultimately may lead to chronic infection. 
Recent evidence has suggested the involvement of IL-10-independent mechanisms in S. aureus-induced 
immunomodulation. S. aureus or its PGN are able to down-regulate staphylococcal SAg-induced 
expression of chemokines such as CXCL10, and prevent T cell recruitment. Such a regulation is not due 
to IL-10 production, but rather to S. aureus-triggered activation of MAPKs p38 and ERK, and inhibition 
of STAT1 signaling (Li et al., manuscript submitted). 
Recently, a study on cutaneous infection by S. aureus has demonstrated a role of Gr1+CD11b+ 
myeloid-derived suppressor cells (MDSCs) in immunomodulation [16]. Signaling through TLR2/6 but 
not TLR2/1 in skin resident cells triggers production of IL-6, which induces the accumulation of MDSCs. 
MDSCs are recruited to skin and suppress T cell-mediated recall responses. Bacterial lipoproteins are 
essential for this immune suppression. A chronic S. aureus infection model has corroborated the 
important role of MDSC in immunosuppression [58]. In this study, a robust IL-10 and TGF-β response 
was observed, but it was not essential for the immunosuppressive effect. In addition, Tregs did not play 
a significant role in either infection model. 
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4. Molecular Mechanisms of Immunomodulation by S. aureus 
In addition to the pro-inflammatory properties, the cell wall of S. aureus can trigger an anti-inflammatory 
response. Emerging evidence indicates that TLR2 ligands embedded in staphylococcal cell wall are 
involved in S. aureus-induced immunomodulation. LTA is one of these ligands that down-regulates host 
innate and adaptive immune responses [43,59]. However, LTA is unlikely to be the only anti-
inflammatory molecule, since PGN induces more IL-10 than LTA alone [15]. Furthermore, we detected 
higher induction of IL-10 by heat-killed S. aureus than commercially prepared staphylococcal PGN, 
which implies that ligands other than PGN-derived molecules are responsible for the immunomodulation. 
The exact immune regulatory molecules still need to be identified. In addition to cell wall components, 
the staphylococcal secreted protein Map (MHC class II analog protein) can act as an immunomodulator 
that interferes with T cell-mediated responses [60], although the molecular mechanism is yet to  
be investigated. 
Recent studies have demonstrated that the pro-inflammatory properties and immunomodulatory 
properties of S. aureus can be uncoupled. Nasal S. aureus isolates have a different IL-10-inducing 
capacity, which does not correlate with the TNFα-inducing capacity [22]. The composition of the S. 
aureus cell wall may induce the formation of different TLR2 signaling complexes. The balance between 
these receptor complexes may determine the difference in anti-inflammatory capacity. For example, 
TLR2/6 dimers, rather than TLR2/1 dimers, have been often linked to immunomodulation [42]. 
Accessory molecules CD14 and CD36 are not required for IL-10 production, whereas CD14 is required 
for the pro-inflammatory response [15]. Phagocytosis and phagosomal processing of S. aureus are 
required for the pro- but not the anti-inflammatory response [22]. In addition, different intracellular 
signaling pathways also account for different immune responses to S. aureus. The PI3K/Akt/mTOR and 
extracellular signal-regulated kinase (ERK) pathways are responsible for the immunomodulation, while 
the MAPK p38 pathway is essential for pro-inflammatory response [22]. The MyD88 adaptor-like 
molecule TIRAP, but not MyD88, has been linked with TLR2/6-induced PI3K activation [61]. 
Signaling from TLRs trigger activation and nuclear translocation of several transcription factors that 
drive IL-10 expression. NFκB [62], C/EBPβ [63,64], ATF1 [65], IRF1 [66], STAT3 [66], and the 
transcription factors specific protein 1 (SP1) [67] and SP3 [68] complex at the IL-10 promoter to initiate 
IL-10 transcription in monocytes and macrophages. 
The properties of immunomodulation and commensalism by S. aureus might be determined by 
several factors, such as the site of infection, strain of S. aureus, host genetics, host diet and environment. 
The nostril is a common commensal colonization site of S. aureus, while skin colonization by this 
microbe is usually associated with disease, such as AD (Figure 1). In blood, infection by S. aureus can 
lead to severe sepsis. Capacity of immunomodulation by S. aureus varies among community isolates, 
which is uncoupled with its inflammatory capacity [22]. Higher IL-10-inducing isolates may have better 
colonization capacity, due to the tolerogenic environment generated by IL-10. A study on single 
nucleotide polymorphisms showed that human genetics play an important role in determining persistent 
nasal S. aureus carriage [69]. Although genotypes of C-reactive protein (CRP) and IL-4 are suggested 
to be the determinants, the detailed mechanism is still unknown. Diet and living conditions also affect 
S. aureus-host interaction. For example, the addition of vitamin D to a bovine mammary epithelial cell 
culture enhances the IL-10 response to S. aureus [70]. 




Figure 1. The outcome of S. aureus detection depends on the site of infection. In nostrils, 
macrophages, the primary antigen-presenting cells (APCs), produce high levels of IL-10 upon S. 
aureus stimulation, which promote commensalism and disease tolerance to S. aureus, and 
ultimately staphylococcal carriage. Upon cutaneous infection by S. aureus, myeloid-derived 
suppressor cells (MDSCs) are recruited to the skin and regulate T cell-mediated recall responses, 
which may facilitate disease tolerance to the microbe. In addition, Langerhans cells are the main 
APCs in skin, which activate a robust TH1/TH17 response, resulting in bacterial clearance. In blood, 
the primary APCs are monocytes, which produce abundant IL-10 upon staphylococcal infection. 
This facilitates immune evasion and may lead to sepsis. The human body illustration is from 
wiseGEEk (http://www.wisegeek.org/how-many-muscles-are-there-in-the-human-body.htm# 
anatomy-of-human-muscle). DC: dendritic cell; MDSC: myeloid-derived suppressor cell;  
IL-10: interleukin-10. 
In addition to IL-10, TGF-β can play an anti-inflammatory role in microbe-induced 
immunomodulation [71]. For example, Streptococcus pneumoniae induces TGF- β expression and drives 
Treg infiltration, which is essential for pneumococci-induced immunomodulation and chronic  
carriage [72]. S. aureus can also induce production of TGF- β in several infection models [58,73]. 
However, the expression of TGF- β did not contribute to the immunosuppressive effect of S. aureus in 
this study [58]. 
5. Mechanisms of Disease Tolerance to S. aureus 
During infection, S. aureus causes extensive tissue damage to its host either directly by its virulence 
factors (e.g., α-toxin), or through hyper-activation of the host immune system (e.g., immunopathology 
induced by staphylococcal SAg). The mechanisms of S. aureus-induced damage are balanced by 
“disease tolerance” mechanisms that prevent unnecessary tissue destruction caused by the microbe or 
the host [74]. Disease tolerance improves host fitness by limiting pathology and reducing mortality 
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without directly affecting microbial burden [75]. These mechanisms are different from disease resistance 
mechanisms that aim at clearing the microbe. Disease tolerance has been reported in a variety of infection 
models [76–78]. Whether these mechanisms are involved in the establishment of commensalism is not 
yet known, but it is likely given that tissue integrity is a feature of commensalism. We hypothesize that 
disease tolerance is not only essential to limit S. aureus-induced tissue damage and pathology during 
infection but also for S. aureus to establish commensalism. 
The importance of disease tolerance in limiting S. aureus pathogenesis was recently highlighted by 
the observation that autophagy prevents tissue damage caused by α-toxin [79]. In this study, the authors 
found that autophagy-deficient mice (i.e., Atg16L1HM mice) were susceptible to S. aureus pneumonia 
and sepsis independently of bacterial burden. They established that susceptibility was conferred by 
production of the S. aureus α-toxin, and that autophagy down-regulated the expression of the α-toxin 
receptor ADAM10 in epithelial cells, thereby limiting damage during S. aureus infection. Interestingly, 
anthracyclines, a family of DNA damaging chemotherapeutic agents, also induced autophagy in the lung 
and protected mice from cecal-ligation and puncture sepsis [78], suggesting autophagy in the lung is an 
important disease tolerance mechanism to sepsis and, perhaps, other systemic S. aureus infections. 
Whether a similar effect is seen in the upper respiratory tract during S. aureus commensalism is currently 
unknown. However, given the importance of the integrity of the nasal epithelial layer during 
commensalism, it is reasonable to speculate that autophagy in the nose would confer disease tolerance 
to S. aureus as well. Indeed, autophagy-deficiencies have been identified in nasal polyps [80], and 
staphylococcal exotoxins have been found to dysregulate epithelium integrity [81,82]. Moreover, α-toxin 
expression in the nose is low [83,84], perhaps as a deliberate effort by S. aureus to limit pathology. It is, 
therefore, likely that autophagy mediates disease tolerance in the nose to promote S. aureus commensalism. 
The hyper-active immune response during staphylococcal systemic complications causes severe 
tissue damage through immunopathology. In particular, the cytokine storm resulting from massive T cell 
activation by SAgs leads to multi-organ failure, a hallmark of staphylococcal TSS [85,86]. Any reduction 
of such an exacerbated immune response would likely slow down this progression and provide the host 
with additional time to clear the infection without the devastating immunopathology. We have 
previously shown that the IL-10 response induced by the staphylococcal cell wall is highly effective in 
suppressing SAg-induced T cell activation, and prolonging survival in a mouse model of staphylococcal 
TSS [42]. This mode of action likely has little effect on bacterial burden, but rather limits 
immunopathology by the over-active immune response. In support of this, staphylococcal TSS rarely 
develops (less than 5% of the time) during staphylococcal bacteremia [87,88], most likely because of 
elevated IL-10 levels [57] that protect against extensive tissue damage. 
The breakdown of disease tolerance during staphylococcal TSS may explain the shortage of current 
treatments. The limited success of many of these treatments may be due to the focus on eliminating the 
microbe, and ignoring the extensive tissue damage that is occurring. Implementing treatment strategies 
that combine tissue damage control and antibiotics that inhibit toxin production (e.g., clindamycin [89]) 
may provide the most effective approach to combat TSS and other staphylococcal systemic infections.  
Similar to staphylococcal TSS, immunomodulation through IL-10 may play a disease tolerance role 
during S. aureus commensalism. IL-10 is an essential anti-inflammatory molecule that mediates 
tolerance to the gut microbiota, and mutations and/or deficiencies in IL-10 cause severe enterocolitis in 
mice [90] and humans [91]. We predict a similar effect in the nose whereby IL-10 promotes S. aureus 
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commensalism by limiting the inflammatory response to S. aureus and tissue damage caused by its 
toxins. For example, IL-10 would protect against nasal epithelium dysregulation caused by staphylococcal 
SAgs [92]. Indeed, nasal S. aureus isolates do carry SAgs as frequently as clinical isolates [39], but are 
not causing disease. Moreover, unlike Streptococcus pyogenes [93], staphylococcal SAgs are not 
required for S. aureus colonization in an HLA-DR4 transgenic mouse [22], perhaps due to the more 
robust IL-10 response it induces [42]. Higher IL-10 levels in the nasal epithelium are also associated 
with better tolerance to house dust mite allergens [94,95]. Unfortunately, studies on the function of  
IL-10 in the nose as it pertains to commensals are lacking. Nonetheless, the role of IL-10 in regulating 
S. aureus commensalism is an intriguing possibility that must be explored further. Additional disease 
tolerance mechanisms by particular receptors (e.g., aryl hydrocarbon receptor [96]) reported for other 
inflammatory conditions remain to be tested in S. aureus infections. 
6. Mechanisms of Immune Evasion by S. aureus 
Another important aspect of S. aureus pathobiosis is the ability of this microbe to evade the host 
immune response. Immune evasion can be broadly classified into two main types: evasion by avoiding 
host detection, or evasion by modulating the host immune response. Here, we will only briefly  
outline the mechanisms of S. aureus immune evasion as they have been recently reviewed extensively 
elsewhere [97,98]. 
To avoid detection, S. aureus produces a plethora of virulence factors to avert the essential 
components of the host immune response involved in the elimination of S. aureus. These include the 
complement system, leukocyte recruitment mechanisms, and phagocyte function. For example, S. aureus 
has developed multiple, parallel strategies to subvert opsonization and chemotaxis by the complement 
system. Some examples are the staphylococcal C3 convertase assembly inhibitor [99], fibrinogen-binding 
proteins that prevent C3b deposition on the staphylococcal cell wall [100] and C3 conversion to C3b [101], 
and proteases that cleave C3b into an inactive form [102]. In addition to inhibiting C3b, S. aureus also 
inhibits the anaphylatoxins C3a and C5a through proteolysis [102,103], or through receptor antagonism 
by chemotaxis inhibitor protein of S. aureus (CHIPS) [104]. The redundant effects of these 
staphylococcal molecules almost completely inactivate the complement system and facilitate  
immune evasion. 
Professional phagocytes are the most effective cells in battling S. aureus. As such, S. aureus has 
evolved multiple mechanisms to avoid them by regulating their recruitment and function. For example, 
capsule-producing S. aureus are more resistant to phagocytosis and killing [105,106], induce less  
pro-inflammatory cytokine production [107], and are associated with worse infections [108]. Moreover, 
staphylococcal protein A, the most abundant protein in the staphylococcal cell wall, binds Fc receptors 
on the surface of phagocytes and prevents antibody-mediated phagocytosis [109]. If engulfed by 
phagocytic cells, S. aureus can resist the oxidative burst by producing superoxide dismutase and catalase 
to reduce superoxide and hydrogen peroxide into non-lethal compounds [110,111]. S. aureus can also 
mask the MAMPs in its PGN layer with wall teichoic acids [112] or by acetylation of the PGN backbone 
that resist lysozyme cleaving [113], avoiding detection by intracellular PRRs [113]. Moreover, as 
described above, mechanisms that prevent phagocytosis or phagosomal processing of S. aureus may also 
contribute to this immune evasion strategy by limiting the pro-inflammatory response while maintaining 
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the IL-10 induction [22]. In fact, IL-10 itself may contribute to the modulation of phagolysosome 
formation and function, as seen during Mycobacterium tuberculosis infection [114,115]. Altogether, 
these evasion strategies limit the recognition and clearance of S. aureus by professional phagocytes. 
More pertinent to this review is the fact that S. aureus can evade its host by modulating the immune 
response it triggers. The staphylococcal adenosine synthase A (AdsA) is a PGN-anchored protein that 
converts adenosine phosphates (e.g., AMP, ADP, and ATP) to adenosine, a potent anti-inflammatory 
molecule. S. aureus strains deficient in AdsA are more susceptible to neutrophil killing and cause less 
severe disease in mouse models of staphylococcal infections [116]. Adenosine suppresses neutrophil 
degranulation and extracellular trap formation [117], decreases IL-12 production, and impairs T cell 
stimulation by DCs [118,119]. It also directly acts on T cells to promote the differentiation into type 1 
regulatory T cells (Tr1), and to enhance their IL-10 production [120]. Collectively, the anti-inflammatory 
effects of adenosine tailor the host adaptive immune response away from a TH1/TH17 clearance response 
and towards an immunomodulatory phenotype that promotes microbial survival and colonization. 
Therefore, AdsA is an important staphylococcal virulence factors that promotes evasion by modulating 
the host immune response. 
In addition to the mechanisms mentioned above, S. aureus can also alter the response of neutrophils 
to promote its survival upon phagocytosis. Although neutrophils are essential for the clearance of  
S. aureus, their recruitment to the site of infection is associated with enhanced bacterial burden and 
pathogenicity [24]. This implies S. aureus has developed mechanisms to evade neutrophil function. One 
mechanism involves S. aureus upregulating the “don’t eat me” signal CD47 on neutrophils to prevent 
their uptake by responding macrophages [23]. This prolonged neutrophil survival enables S. aureus to 
trigger a specific type of neutrophil cell death program that releases viable S. aureus into the extracellular 
environment [23]. Thus, in certain circumstances, a strong TH17 response that recruits many neutrophils 
may end up benefiting the microbe more than the host. 
The robust IL-10 response that S. aureus induces can also promote immune evasion through 
modulation of the host response in a site-dependent manner [10]. Similar to adenosine, IL-10 can  
down-regulate the expression of MHC class II [121] and co-stimulatory molecules [122], and can inhibit 
pro-inflammatory cytokine production [123] and TH1 responses [124]. The immune evasion effect of 
IL-10 is best seen in patients with staphylococcal bacteremia, where elevated IL-10 levels are associated 
with mortality [57]. This robust modulation of the host immune response, by suppressing macrophage 
and neutrophil migration and function and by down-regulating the adaptive TH1/TH17 responses, allows 
S. aureus to spread and cause severe invasive infections. A similar observation has been described for 
Bordetella [125] and may be applicable to other microbes since an IL-10 response has been linked to 
other PRRs in addition to TLR2. 
7. Clinical Implications and Future Prospects 
Current treatments for staphylococcal infections rely heavily on antibiotics, which will select for 
antibiotic-resistance strains (e.g., MRSA) [126].  Despite significant efforts, no staphylococcal vaccine has 
shown clinical protective efficacy [32,127,128]. Therefore, discovery of alternative anti-staphylococcal 
treatments is a high priority. The understanding of immunomodulation by S. aureus may facilitate the 
development of new methods to prevent and treat staphylococcal infections. 
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The observation of recurrent infections by S. aureus in a given individual suggests that the initial 
infection does not generate host protective immunity to subsequent infections [1]. The reason why it is 
so difficult to develop effective immunity against S. aureus can be partially explained by immunomodulation. 
For example, SpA binds to IgG antibodies and acts as a B cell SAg, limiting host responses to other 
staphylococcal virulence factors [129]. In addition, IL-10-mediated immunomodulation may also 
participate in the failure of S. aureus vaccination by limiting T cell activation and help. Therefore, 
purification of a low IL-10-inducing staphylococcal antigen can be considered as a strategy for  
vaccine development. 
As discussed above, IL-10 plays an important role in S. aureus-induced immunomodulation,  
down-regulating SAg-induced T cell activation, and preventing TSS. Thus, IL-10 is a potential 
therapeutic agent in inflammatory diseases. Indeed, administration of recombinant IL-10 is protective in 
a mouse model of TSS [130,131]. However, its application in humans is limited by its low bioavailability 
and by its toxicity [132]. 
The pro-inflammatory and immunomodulatory properties of S. aureus can be uncoupled and are 
mediated by different signaling pathways [22]. One would expect that shutting down one pathway and 
enhancing the other using chemical inhibitors could be a treatment for staphylococcal infection. 
However, these signaling cascades, i.e., PI3K/Akt/mTOR and MAPKs, are usually involved in many 
aspects of cellular function. Therefore, direct manipulation of these signaling cascades is likely to cause 
numerous side effects. For example, pan-class I PI3K inhibitors, used to treat rheumatoid arthritis (RA), 
have been reported to cause hyperglycemia, gastrointestinal symptoms, and psychiatric side effects [133]. 
Similarly, the PI3K inhibitors used for cancer treatment also have adverse effects with a high risk of 
microbial infections [134,135]. MAPK p38 plays a pivotal role in pro-inflammatory responses to 
infections, and this provides the rationale for it being a therapeutic target. Despite the high efficacy in 
treating autoimmune disorders in mouse models [136], the results from clinical trials with these 
compounds are disappointing, as they lack long-term efficacy [137–140]. 
Staphylococcal cell wall-embedded TLR2 ligands are predominantly responsible for S. aureus-induced 
immunomodulation. Compared with heat-killed S. aureus, clindamycin-treated S. aureus better 
preserves the anti-inflammatory properties, in terms of IL-10-inducing capacity [22]. This illustrates the 
importance of an intact cell wall for the immunomodulation capacity of S. aureus. In line with this 
observation, clinical data show that treating TSS with bacteriostatic antibiotics (e.g., clindamycin) is 
more effective and has better clinical outcomes than bactericidal antibiotics [89,141]. 
The uncoupling of the immunomodulatory properties from the pro-inflammatory properties of  
S. aureus opens up the search for anti-inflammatory ligands in the cell wall. The study on the uncoupling 
of responses to S. aureus suggests that the staphylococcal cell wall contains qualitatively different TLR2 
ligands with distinct IL-10-inducing capacities. Although the anti-inflammatory TLR2 ligands are yet to 
be identified, it is very unlikely that a single ligand will solely induce IL-10 without inducing  
pro-inflammatory cytokines. However, identification of a predominant IL-10-inducing TLR2 ligand may 
provide a template for novel immunomodulatory drug development. 
  




S. aureus is very effective at immunomodulating innate and adaptive immune responses, to promote 
either disease tolerance or immune evasion. The type of immune response to S. aureus that will develop 
is determined by various factors, such as site of infection, bacterial virulence and host genetics, all 
together translating into distinct clinical outcomes. A better understanding of the mechanisms of 
immunomodulation leading to disease tolerance and commensalism will provide further insights into 
staphylococcal diseases and the development of novel clinical treatments for these conditions. 
Acknowledgments 
We thank members of the Madrenas laboratory for helpful discussions. This work was supported in 
part by Canadian Institutes of Health Research (CIHR). A.G.P. is a Fonds de la Recherche en Santé du 
Québec Research Scholar. J.M. holds a Tier I Canada Research Chair in Human Immunology. 
Author Contribution 
Zhigang Li, Adam G. Peres and Andreea C. Damian wrote and reviewed the manuscript. Joaquín 
Madrenas reviewed the manuscript. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Lowy, F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339, 520–532. 
2. Brown, A.F.; Leech, J.M.; Rogers, T.R.; McLoughlin, R.M. Staphylococcus aureus colonization: 
Modulation of host immune response and impact on human vaccine design. Front. Immunol. 2014, 
4, 507. 
3. Chen, L.F. The changing epidemiology of methicillin-resistant Staphylococcus aureus: 50 years of 
a superbug. Am. J. Infect. Control 2013, 41, 448–451. 
4. Miller, L.S.; Cho, J.S. Immunity against Staphylococcus aureus cutaneous infections. Nat. Rev. 
Immunol. 2011, 11, 505–518. 
5. Dantes, R.; Mu, Y.; Belflower, R.; Aragon, D.; Dumyati, G.; Harrison, L.H.; Lessa, F.C.; Lynfield, R.; 
Nadle, J.; Petit, S.; et al. National burden of invasive methicillin-resistant Staphylococcus aureus 
infections, united states, 2011. JAMA Intern. Med. 2013, 173, 1970–1978. 
6. Stentzel, S.; Sundaramoorthy, N.; Michalik, S.; Nordengrun, M.; Schulz, S.; Kolata, J.; Kloppot, P.; 
Engelmann, S.; Steil, L.; Hecker, M.; et al. Specific serum igg at diagnosis of Staphylococcus 
aureus bloodstream invasion is correlated with disease progression. J. Proteom. 2015, 128, 1–7. 
7. Wertheim, H.F.; Melles, D.C.; Vos, M.C.; van Leeuwen, W.; van Belkum, A.; Verbrugh, H.A.; 
Nouwen, J.L. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 
2005, 5, 751–762. 
Pathogens 2015, 4 806 
 
 
8. Bar-Gal, G.K.; Blum, S.E.; Hadas, L.; Ehricht, R.; Monecke, S.; Leitner, G. Host-specificity of 
Staphylococcus aureus causing intramammary infections in dairy animals assessed by genotyping 
and virulence genes. Vet. Microbiol. 2015, 176, 143–154. 
9. Pishchany, G.; McCoy, A.L.; Torres, V.J.; Krause, J.C.; Crowe, J.E., Jr.; Fabry, M.E.; Skaar, E.P. 
Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe 
2010, 8, 544–550. 
10. Peres, A.G.; Madrenas, J. The broad landscape of immune interactions with Staphylococcus 
aureus: From commensalism to lethal infections. Burns 2013, 39, 380–388. 
11. Wertheim, H.F.; Vos, M.C.; Ott, A.; van Belkum, A.; Voss, A.; Kluytmans, J.A.; van Keulen, P.H.; 
Vandenbroucke-Grauls, C.M.; Meester, M.H.; Verbrugh, H.A. Risk and outcome of nosocomial 
Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364,  
703–705. 
12. Netsvyetayeva, I.; Fraczek, M.; Piskorska, K.; Golas, M.; Sikora, M.; Swoboda-Kopec, E.; 
Mlynarczyk, A.; Marusza, W.; Palmieri, B.; Iannitti, T. Staphylococcus aureus nasal carriage in 
ukraine: Antibacterial resistance and virulence factor encoding genes. BMC Infect. Dis. 2014, 14, 
128. 
13. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on toll-like 
receptors. Nat. Immunol. 2010, 11, 373–384. 
14. Figdor, C.G.; van Kooyk, Y.; Adema, G.J. C-type lectin receptors on dendritic cells and langerhans 
cells. Nat. Rev. Immunol. 2002, 2, 77–84. 
15. Frodermann, V.; Chau, T.A.; Sayedyahossein, S.; Toth, J.M.; Heinrichs, D.E.; Madrenas, J. A 
modulatory interleukin-10 response to staphylococcal peptidoglycan prevents Th1/Th17 adaptive 
immunity to Staphylococcus aureus. J Infect Dis 2011, 204, 253–262. 
16. Skabytska, Y.; Wolbing, F.; Gunther, C.; Koberle, M.; Kaesler, S.; Chen, K.M.; Guenova, E.; 
Demircioglu, D.; Kempf, W.E.; Volz, T.; et al. Cutaneous innate immune sensing of toll-like 
receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. 
Immunity 2014, 41, 762–775. 
17. Takeuchi, O.; Hoshino, K.; Akira, S. Cutting edge: TLR2-deficient and MyD88-deficient mice are 
highly susceptible to Staphylococcus aureus infection. J. Immunol. 2000, 165, 5392–5396. 
18. Von Bernuth, H.; Picard, C.; Jin, Z.; Pankla, R.; Xiao, H.; Ku, C.L.; Chrabieh, M.; Mustapha, I.B.; 
Ghandil, P.; Camcioglu, Y.; et al. Pyogenic bacterial infections in humans with MyD88 deficiency. 
Science 2008, 321, 691–696. 
19. Alsina, L.; Israelsson, E.; Altman, M.C.; Dang, K.K.; Ghandil, P.; Israel, L.; von Bernuth, H.; 
Baldwin, N.; Qin, H.; Jin, Z.; et al. A narrow repertoire of transcriptional modules responsive to 
pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MyD88 or IRAK4. 
Nat. Immunol. 2014, 15, 1134–1142. 
20. Tomlinson, G.; Chimalapati, S.; Pollard, T.; Lapp, T.; Cohen, J.; Camberlein, E.; Stafford, S.; 
Periselneris, J.; Aldridge, C.; Vollmer, W.; et al. TLR-mediated inflammatory responses to 
streptococcus pneumoniae are highly dependent on surface expression of bacterial lipoproteins.  
J. Immunol. 2014, 193, 3736–3745. 
21. Takeuchi, O.; Akira, S. Pattern recognition receptors and inflammation. Cell 2010, 140, 805–820. 
Pathogens 2015, 4 807 
 
 
22. Peres, A.G.; Stegen, C.; Li, J.; Xu, A.Q.; Levast, B.; Surette, M.G.; Cousineau, B.; Desrosiers, M.; 
Madrenas, J. Uncoupling of pro- and anti-inflammatory properties of Staphylococcus aureus. 
Infect. Immun. 2015, 83, 1587–1597. 
23. Greenlee-Wacker, M.C.; Rigby, K.M.; Kobayashi, S.D.; Porter, A.R.; DeLeo, F.R.; Nauseef, W.M. 
Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis 
and induces programmed necrosis. J. Immunol. 2014, 192, 4709–4717. 
24. McLoughlin, R.M.; Lee, J.C.; Kasper, D.L.; Tzianabos, A.O. Ifn-gamma regulated chemokine 
production determines the outcome of Staphylococcus aureus infection. J. Immunol. 2008, 181, 
1323–1332. 
25. Montgomery, C.P.; Daniels, M.; Zhao, F.; Alegre, M.L.; Chong, A.S.; Daum, R.S. Protective 
immunity against recurrent Staphylococcus aureus skin infection requires antibody and 
interleukin-17a. Infect. Immun. 2014, 82, 2125–2134. 
26. Milner, J.D.; Brenchley, J.M.; Laurence, A.; Freeman, A.F.; Hill, B.J.; Elias, K.M.; Kanno, Y.; 
Spalding, C.; Elloumi, H.Z.; Paulson, M.L.; et al. Impaired T(h)17 cell differentiation in subjects 
with autosomal dominant hyper-ige syndrome. Nature 2008, 452, 773–776. 
27. Soltesz, B.; Toth, B.; Sarkadi, A.K.; Erdos, M.; Marodi, L. The evolving view of IL-17-mediated 
immunity in defense against mucocutaneous candidiasis in humans. Int. Rev. Immunol. 2015, 34, 
348–363. 
28. Okada, S.; Markle, J.G.; Deenick, E.K.; Mele, F.; Averbuch, D.; Lagos, M.; Alzahrani, M.;  
Al-Muhsen, S.; Halwani, R.; Ma, C.S.; et al. Immunodeficiencies. Impairment of immunity to 
candida and mycobacterium in humans with bi-allelic rorc mutations. Science 2015, 349, 606–613. 
29. Grumann, D.; Scharf, S.S.; Holtfreter, S.; Kohler, C.; Steil, L.; Engelmann, S.; Hecker, M.; Volker, U.; 
Broker, B.M. Immune cell activation by enterotoxin gene cluster (egc)-encoded and non-egc 
superantigens from Staphylococcus aureus. J. Immunol. 2008, 181, 5054–5061. 
30. Dauwalder, O.; Thomas, D.; Ferry, T.; Debard, A.L.; Badiou, C.; Vandenesch, F.; Etienne, J.; Lina, G.; 
Monneret, G. Comparative inflammatory properties of staphylococcal superantigenic enterotoxins 
sea and seg: Implications for septic shock. J. Leukoc Biol. 2006, 80, 753–758. 
31. Kolata, J.B.; Kuhbandner, I.; Link, C.; Normann, N.; Vu, C.H.; Steil, L.; Weidenmaier, C.;  
Broker, B.M. The fall of a dogma? Unexpected high T-cell memory response to Staphylococcus 
aureus in humans. J. Infect. Dis. 2015, 212, 830–838. 
32. Schlievert, P.M. The dream of staphylococcal vaccination. J. Exp. Med. 2014, 211, 2326. 
33. Lee, C.C.; Avalos, A.M.; Ploegh, H.L. Accessory molecules for toll-like receptors and their 
function. Nat. Rev. Immunol. 2012, 12, 168–179. 
34. Hasan, U.; Chaffois, C.; Gaillard, C.; Saulnier, V.; Merck, E.; Tancredi, S.; Guiet, C.; Briere, F.; 
Vlach, J.; Lebecque, S.; et al. Human TLR10 is a functional receptor, expressed by B cells and 
plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 
2005, 174, 2942–2950. 
35. Oosting, M.; Cheng, S.C.; Bolscher, J.M.; Vestering-Stenger, R.; Plantinga, T.S.; Verschueren, I.C.; 
Arts, P.; Garritsen, A.; van Eenennaam, H.; Sturm, P.; et al. Human TLR10 is an anti-inflammatory 
pattern-recognition receptor. Proc. Natl. Acad. Sci. USA 2014, 111, E4478–E4484. 
36. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. 
Clin. Microbiol. Rev. 2009, 22, 240–273. 
Pathogens 2015, 4 808 
 
 
37. Becker, K.; Friedrich, A.W.; Lubritz, G.; Weilert, M.; Peters, G.; von Eiff, C. Prevalence of genes 
encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus 
aureus isolated from blood and nasal specimens. J. Clin. Microbiol. 2003, 41, 1434–1439. 
38. Mempel, M.; Lina, G.; Hojka, M.; Schnopp, C.; Seidl, H.P.; Schafer, T.; Ring, J.; Vandenesch, F.; 
Abeck, D. High prevalence of superantigens associated with the egc locus in Staphylococcus 
aureus isolates from patients with atopic eczema. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22, 
306–309. 
39. Nashev, D.; Toshkova, K.; Salasia, S.I.; Hassan, A.A.; Lammler, C.; Zschock, M. Distribution of 
virulence genes of Staphylococcus  aureus isolated from stable nasal carriers. FEMS Microbiol. 
Lett. 2004, 233, 45–52. 
40. Davis, J.P.; Chesney, P.J.; Wand, P.J.; LaVenture, M. Toxic-shock syndrome: Epidemiologic 
features, recurrence, risk factors, and prevention. N. Engl. J. Med. 1980, 303, 1429–1435. 
41. Reduced incidence of menstrual toxic-shock syndrome--United States, 1980–1990. MMWR Morb. 
Mortal Wkly Rep. 1990, 39, 421–423. 
42. Chau, T.A.; McCully, M.L.; Brintnell, W.; An, G.; Kasper, K.J.; Vines, E.D.; Kubes, P.;  
Haeryfar, S.M.; McCormick, J.K.; Cairns, E.; et al. Toll-like receptor 2 ligands on the 
staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic 
shock syndrome. Nat. Med. 2009, 15, 641–648. 
43. Lai, Y.; di Nardo, A.; Nakatsuji, T.; Leichtle, A.; Yang, Y.; Cogen, A.L.; Wu, Z.R.; Hooper, L.V.; 
Schmidt, R.R.; von Aulock, S.; et al. Commensal bacteria regulate toll-like receptor 3-dependent 
inflammation after skin injury. Nat. Med. 2009, 15, 1377–1382. 
44. Tkaczyk, C.; Hamilton, M.M.; Datta, V.; Yang, X.P.; Hilliard, J.J.; Stephens, G.L.; Sadowska, A.; 
Hua, L.; O’Day, T.; Suzich, J.; et al. Staphylococcus aureus alpha toxin suppresses effective innate 
and adaptive immune responses in a murine dermonecrosis model. PLoS ONE 2013, 8, e75103. 
45. Hawrylowicz, C.M.; O’Garra, A. Potential role of interleukin-10-secreting regulatory T cells in 
allergy and asthma. Nat. Rev. Immunol. 2005, 5, 271–283. 
46. Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O’Garra, A. Interleukin-10 and the interleukin-
10 receptor. Annu. Rev. Immunol. 2001, 19, 683–765. 
47. Sendide, K.; Deghmane, A.E.; Pechkovsky, D.; Av-Gay, Y.; Talal, A.; Hmama, Z. Mycobacterium 
bovis bcg attenuates surface expression of mature class II molecules through IL-10-dependent 
inhibition of cathepsin s. J. Immunol. 2005, 175, 5324–5332. 
48. Willems, F.; Marchant, A.; Delville, J.P.; Gerard, C.; Delvaux, A.; Velu, T.; de Boer, M.;  
Goldman, M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on 
human monocytes. Eur. J. Immunol. 1994, 24, 1007–1009. 
49. Buelens, C.; Willems, F.; Delvaux, A.; Pierard, G.; Delville, J.P.; Velu, T.; Goldman, M. 
Interleukin-10 differentially regulates B7–1 (CD80) and B7–2 (CD86) expression on human 
peripheral blood dendritic cells. Eur. J. Immunol. 1995, 25, 2668–2672. 
50. Thurlow, L.R.; Hanke, M.L.; Fritz, T.; Angle, A.; Aldrich, A.; Williams, S.H.; Engebretsen, I.L.; 
Bayles, K.W.; Horswill, A.R.; Kielian, T. Staphylococcus aureus biofilms prevent macrophage 
phagocytosis and attenuate inflammation in vivo. J. Immunol. 2011, 186, 6585–6596. 
Pathogens 2015, 4 809 
 
 
51. Hanke, M.L.; Heim, C.E.; Angle, A.; Sanderson, S.D.; Kielian, T. Targeting macrophage activation 
for the prevention and treatment of Staphylococcus aureus biofilm infections. J. Immunol. 2013, 
190, 2159–2168. 
52. Krysko, O.; Holtappels, G.; Zhang, N.; Kubica, M.; Deswarte, K.; Derycke, L.; Claeys, S.; 
Hammad, H.; Brusselle, G.G.; Vandenabeele, P.; et al. Alternatively activated macrophages and 
impaired phagocytosis of S. aureus in chronic rhinosinusitis. Allergy 2011, 66, 396–403. 
53. Xu, F.; Kang, Y.; Zhang, H.; Piao, Z.; Yin, H.; Diao, R.; Xia, J.; Shi, L. Akt1-mediated regulation 
of macrophage polarization in a murine model of Staphylococcus aureus pulmonary infection. J. 
Infect Dis. 2013, 208, 528–538. 
54. Kabelitz, D. Expression and function of toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 
2007, 19, 39–45. 
55. Zielinski, C.E.; Mele, F.; Aschenbrenner, D.; Jarrossay, D.; Ronchi, F.; Gattorno, M.; Monticelli, S.; 
Lanzavecchia, A.; Sallusto, F. Pathogen-induced human Th17 cells produce IFN-gamma or IL-10 
and are regulated by IL-1beta. Nature 2012, 484, 514–518. 
56. Rabe, H.; Nordstrom, I.; Andersson, K.; Lundell, A.C.; Rudin, A. Staphylococcus aureus convert 
neonatal conventional cd4(+) T cells into Foxp3(+) CD25(+) CD127(low) T cells via the PD-1/PD-
lL axis. Immunology 2014, 141, 467–481. 
57. Rose, W.E.; Eickhoff, J.C.; Shukla, S.K.; Pantrangi, M.; Rooijakkers, S.; Cosgrove, S.E.; Nizet, V.; 
Sakoulas, G. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality 
in patients with Staphylococcus aureus bacteremia. J. Infect. Dis. 2012, 206, 1604–1611. 
58. Tebartz, C.; Horst, S.A.; Sparwasser, T.; Huehn, J.; Beineke, A.; Peters, G.; Medina, E. A major 
role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression 
during Staphylococcus aureus infection. J. Immunol. 2015, 194, 1100–1111. 
59. Wang, J.; Roderiquez, G.; Norcross, M.A. Control of adaptive immune responses by 
Staphylococcus aureus through IL-10, PD-L1, and TLR2. Sci. Rep. 2012, 2, 606. 
60. Lee, L.Y.; Miyamoto, Y.J.; McIntyre, B.W.; Hook, M.; McCrea, K.W.; McDevitt, D.; Brown, E.L. 
The Staphylococcus aureus map protein is an immunomodulator that interferes with T cell-mediated 
responses. J. Clin. Invest. 2002, 110, 1461–1471. 
61. Santos-Sierra, S.; Deshmukh, S.D.; Kalnitski, J.; Kuenzi, P.; Wymann, M.P.; Golenbock, D.T.; 
Henneke, P. Mal connects TLR2 to PI3kinase activation and phagocyte polarization. EMBO J. 
2009, 28, 2018–2027. 
62. Cao, S.; Zhang, X.; Edwards, J.P.; Mosser, D.M. Nf-kappab1 (p50) homodimers differentially 
regulate pro- and anti-inflammatory cytokines in macrophages. J. Biol. Chem. 2006, 281,  
26041–26050. 
63. Brenner, S.; Prosch, S.; Schenke-Layland, K.; Riese, U.; Gausmann, U.; Platzer, C. Camp-induced 
interleukin-10 promoter activation depends on ccaat/enhancer-binding protein expression and 
monocytic differentiation. J. Biol. Chem. 2003, 278, 5597–5604. 
64. Liu, Y.W.; Tseng, H.P.; Chen, L.C.; Chen, B.K.; Chang, W.C. Functional cooperation of simian 
virus 40 promoter factor 1 and ccaat/enhancer-binding protein beta and delta in lipopolysaccharide-
induced gene activation of IL-10 in mouse macrophages. J. Immunol. 2003, 171, 821–828. 
Pathogens 2015, 4 810 
 
 
65. Ananieva, O.; Darragh, J.; Johansen, C.; Carr, J.M.; McIlrath, J.; Park, J.M.; Wingate, A.; Monk, C.E.; 
Toth, R.; Santos, S.G.; et al. The kinases msk1 and msk2 act as negative regulators of toll-like 
receptor signaling. Nat. Immunol. 2008, 9, 1028–1036. 
66. Ziegler-Heitbrock, L.; Lotzerich, M.; Schaefer, A.; Werner, T.; Frankenberger, M.; Benkhart, E. 
Ifn-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and stat3.  
J. Immunol. 2003, 171, 285–290. 
67. Brightbill, H.D.; Plevy, S.E.; Modlin, R.L.; Smale, S.T. A prominent role for sp1 during 
lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J. Immunol. 2000, 
164, 1940–1951. 
68. Tone, M.; Powell, M.J.; Tone, Y.; Thompson, S.A.; Waldmann, H. IL-10 gene expression is 
controlled by the transcription factors sp1 and sp3. J. Immunol. 2000, 165, 286–291. 
69. Ruimy, R.; Angebault, C.; Djossou, F.; Dupont, C.; Epelboin, L.; Jarraud, S.; Lefevre, L.A.; Bes, M.; 
Lixandru, B.E.; Bertine, M.; et al. Are host genetics the predominant determinant of persistent 
nasal Staphylococcus aureus carriage in humans? J. Infect. Dis. 2010, 202, 924–934. 
70. Alva-Murillo, N.; Tellez-Perez, A.D.; Medina-Estrada, I.; Alvarez-Aguilar, C.; Ochoa-Zarzosa, A.; 
Lopez-Meza, J.E. Modulation of the inflammatory response of bovine mammary epithelial cells 
by cholecalciferol (vitamin D) during Staphylococcus aureus internalization. Microb. Pathog. 
2014, 77, 24–30. 
71. Reed, S.G. TGF-beta in infections and infectious diseases. Microbes Infect. 1999, 1, 1313–1325. 
72. Neill, D.R.; Coward, W.R.; Gritzfeld, J.F.; Richards, L.; Garcia-Garcia, F.J.; Dotor, J.; Gordon, S.B.; 
Kadioglu, A. Density and duration of pneumococcal carriage is maintained by transforming growth 
factor beta1 and T regulatory cells. Am. J. Respir. Crit. Care Med. 2014, 189, 1250–1259. 
73. Andreotti, C.S.; Pereyra, E.A.; Baravalle, C.; Renna, M.S.; Ortega, H.H.; Calvinho, L.F.; Dallard, B.E. 
Staphylococcus aureus chronic intramammary infection modifies protein expression of transforming 
growth factor beta (TGF-beta) subfamily components during active involution. Res. Vet. Sci. 2014, 
96, 5–14. 
74. Soares, M.P.; Gozzelino, R.; Weis, S. Tissue damage control in disease tolerance. Trends Immunol. 
2014, 35, 483–494. 
75. Medzhitov, R.; Schneider, D.S.; Soares, M.P. Disease tolerance as a defense strategy. Science 
2012, 335, 936–941. 
76. Raberg, L.; Sim, D.; Read, A.F. Disentangling genetic variation for resistance and tolerance to 
infectious diseases in animals. Science 2007, 318, 812–814. 
77. Larsen, R.; Gozzelino, R.; Jeney, V.; Tokaji, L.; Bozza, F.A.; Japiassu, A.M.; Bonaparte, D.; 
Cavalcante, M.M.; Chora, A.; Ferreira, A.; et al. A central role for free heme in the pathogenesis 
of severe sepsis. Sci. Transl. Med. 2010, 2, 51ra71. 
78. Figueiredo, N.; Chora, A.; Raquel, H.; Pejanovic, N.; Pereira, P.; Hartleben, B.; Neves-Costa, A.; 
Moita, C.; Pedroso, D.; Pinto, A.; et al. Anthracyclines induce DNA damage response-mediated 
protection against severe sepsis. Immunity 2013, 39, 874–884. 
79. Maurer, K.; Reyes-Robles, T.; Alonzo, F., 3rd; Durbin, J.; Torres, V.J.; Cadwell, K. Autophagy 
mediates tolerance to Staphylococcus aureus alpha-toxin. Cell Host Microbe 2015, 17, 429–440. 
Pathogens 2015, 4 811 
 
 
80. Chen, J.Y.; Hour, T.C.; Yang, S.F.; Chien, C.Y.; Chen, H.R.; Tsai, K.L.; Ko, J.Y.; Wang, L.F. 
Autophagy is deficient in nasal polyps: Implications for the pathogenesis of the disease. Int. Forum. 
Allergy Rhinol. 2015, 5, 119–123. 
81. Hermann, I.; Rath, S.; Ziesemer, S.; Volksdorf, T.; Dress, R.J.; Gutjahr, M.; Muller, C.; Beule, A.G.; 
Hildebrandt, J.P. Staphylococcus aureus hemolysin a disrupts cell-matrix adhesions in human 
airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2015, 52, 14–24. 
82. Malik, Z.; Roscioli, E.; Murphy, J.; Ou, J.; Bassiouni, A.; Wormald, P.J.; Vreugde, S. 
Staphylococcus aureus impairs the airway epithelial barrier in vitro. Int. Forum. Allergy Rhinol. 
2015, 5, 551–556. 
83. Burian, M.; Wolz, C.; Goerke, C. Regulatory adaptation of Staphylococcus aureus during nasal 
colonization of humans. PLoS ONE 2010, 5, e10040. 
84. Jenkins, A.; Diep, B.A.; Mai, T.T.; Vo, N.H.; Warrener, P.; Suzich, J.; Stover, C.K.; Sellman, B.R. 
Differential expression and roles of Staphylococcus aureus virulence determinants during 
colonization and disease. mBio 2015, 6, e02272–02214. 
85. Todd, J.; Fishaut, M.; Kapral, F.; Welch, T. Toxic-shock syndrome associated with phage-group-i 
staphylococci. Lancet 1978, 2, 1116–1118. 
86. McCormick, J.K.; Yarwood, J.M.; Schlievert, P.M. Toxic shock syndrome and bacterial 
superantigens: An update. Annu. Rev. Microbiol. 2001, 55, 77–104. 
87. Llewelyn, M.; Cohen, J. Superantigens: Microbial agents that corrupt immunity. Lancet Infect. 
Dis. 2002, 2, 156–162. 
88. Murray, R.J. Recognition and management of Staphylococcus aureus toxin-mediated disease. 
Intern. Med. J. 2005, 35 (Suppl. 2), S106–S119. 
89. Annane, D.; Clair, B.; Salomon, J. Managing toxic shock syndrome with antibiotics. Expert Opin. 
Pharmacother. 2004, 5, 1701–1710. 
90. Kuhn, R.; Lohler, J.; Rennick, D.; Rajewsky, K.; Muller, W. Interleukin-10-deficient mice develop 
chronic enterocolitis. Cell 1993, 75, 263–274. 
91. Glocker, E.O.; Kotlarz, D.; Boztug, K.; Gertz, E.M.; Schaffer, A.A.; Noyan, F.; Perro, M.; 
Diestelhorst, J.; Allroth, A.; Murugan, D.; et al. Inflammatory bowel disease and mutations 
affecting the interleukin-10 receptor. N. Engl. J. Med. 2009, 361, 2033–2045. 
92. Lu, J.; Philpott, D.J.; Saunders, P.R.; Perdue, M.H.; Yang, P.C.; McKay, D.M. Epithelial ion 
transport and barrier abnormalities evoked by superantigen-activated immune cells are inhibited 
by interleukin-10 but not interleukin-4. J. Pharmacol. Exp. Ther. 1998, 287, 128–136. 
93. Kasper, K.J.; Zeppa, J.J.; Wakabayashi, A.T.; Xu, S.X.; Mazzuca, D.M.; Welch, I.; Baroja, M.L.; 
Kotb, M.; Cairns, E.; Cleary, P.P.; et al. Bacterial superantigens promote acute nasopharyngeal 
infection by Streptococcus pyogenes in a human MHC class II-dependent manner. PLoS Pathog. 
2014, 10, e1004155. 
94. Muller, B.; de Groot, E.J.; Kortekaas, I.J.; Fokkens, W.J.; van Drunen, C.M. Nasal epithelial cells 
express IL-10 at levels that negatively correlate with clinical symptoms in patients with house dust 
mite allergy. Allergy 2007, 62, 1014–1022. 
95. Muller, B.; de Groot, E.J.; Kortekaas, I.J.; Fokkens, W.J.; van Drunen, C.M. Nasal endothelial 
interleukin-10 expression is negatively correlated with nasal symptoms after allergen provocation. 
Allergy 2009, 64, 738–745. 
Pathogens 2015, 4 812 
 
 
96. Bessede, A.; Gargaro, M.; Pallotta, M.T.; Matino, D.; Servillo, G.; Brunacci, C.; Bicciato, S.; 
Mazza, E.M.; Macchiarulo, A.; Vacca, C.; et al. Aryl hydrocarbon receptor control of a disease 
tolerance defence pathway. Nature 2014, 511, 184–190. 
97. Okumura, C.Y.; Nizet, V. Subterfuge and sabotage: Evasion of host innate defenses by invasive 
gram-positive bacterial pathogens. Annu. Rev. Microbiol. 2014, 68, 439–458. 
98. Thammavongsa, V.; Kim, H.K.; Missiakas, D.; Schneewind, O. Staphylococcal manipulation of 
host immune responses. Nat. Rev. Microbiol. 2015, 13, 529–543. 
99. Rooijakkers, S.H.; Ruyken, M.; Roos, A.; Daha, M.R.; Presanis, J.S.; Sim, R.B.; van Wamel, W.J.; 
van Kessel, K.P.; van Strijp, J.A. Immune evasion by a staphylococcal complement inhibitor that 
acts on c3 convertases. Nat. Immunol. 2005, 6, 920–927. 
100. Hair, P.S.; Echague, C.G.; Sholl, A.M.; Watkins, J.A.; Geoghegan, J.A.; Foster, T.J.; Cunnion, K.M. 
Clumping factor a interaction with complement factor i increases c3b cleavage on the bacterial 
surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect. 
Immun. 2010, 78, 1717–1727. 
101. Jongerius, I.; Kohl, J.; Pandey, M.K.; Ruyken, M.; van Kessel, K.P.; van Strijp, J.A.; Rooijakkers, S.H. 
Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 2007, 
204, 2461–2471. 
102. Jusko, M.; Potempa, J.; Kantyka, T.; Bielecka, E.; Miller, H.K.; Kalinska, M.; Dubin, G.; Garred, P.; 
Shaw, L.N.; Blom, A.M. Staphylococcal proteases aid in evasion of the human complement 
system. J. Innate Immun. 2014, 6, 31–46. 
103. Laarman, A.J.; Ruyken, M.; Malone, C.L.; van Strijp, J.A.; Horswill, A.R.; Rooijakkers, S.H. 
Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune 
evasion. J. Immunol. 2011, 186, 6445–6453. 
104. De Haas, C.J.; Veldkamp, K.E.; Peschel, A.; Weerkamp, F.; van Wamel, W.J.; Heezius, E.C.; 
Poppelier, M.J.; van Kessel, K.P.; van Strijp, J.A. Chemotaxis inhibitory protein of Staphylococcus 
aureus, a bacterial antiinflammatory agent. J. Exp. Med. 2004, 199, 687–695. 
105. Thakker, M.; Park, J.S.; Carey, V.; Lee, J.C. Staphylococcus aureus serotype 5 capsular 
polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. 
Infect. Immun. 1998, 66, 5183–5189. 
106. Watts, A.; Ke, D.; Wang, Q.; Pillay, A.; Nicholson-Weller, A.; Lee, J.C. Staphylococcus aureus 
strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect. 
Immun. 2005, 73, 3502–3511. 
107. Ip, W.K.; Sokolovska, A.; Charriere, G.M.; Boyer, L.; Dejardin, S.; Cappillino, M.P.; Yantosca, L.M.; 
Takahashi, K.; Moore, K.J.; Lacy-Hulbert, A.; et al. Phagocytosis and phagosome acidification are 
required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus.  
J. Immunol. 2010, 184, 7071–7081. 
108. Shi, L.; Takahashi, K.; Dundee, J.; Shahroor-Karni, S.; Thiel, S.; Jensenius, J.C.; Gad, F.;  
Hamblin, M.R.; Sastry, K.N.; Ezekowitz, R.A. Mannose-binding lectin-deficient mice are 
susceptible to infection with Staphylococcus aureus. J. Exp. Med. 2004, 199, 1379–1390. 
109. Falugi, F.; Kim, H.K.; Missiakas, D.M.; Schneewind, O. Role of protein A in the evasion of host 
adaptive immune responses by Staphylococcus aureus. mBio 2013, 4, doi:10.1128/mBio.00575-13. 
Pathogens 2015, 4 813 
 
 
110. Mandell, G.L. Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro 
and in vivo studies with emphasis on staphylococcal--leukocyte interaction. J. Clin. Invest. 1975, 
55, 561–566. 
111. Karavolos, M.H.; Horsburgh, M.J.; Ingham, E.; Foster, S.J. Role and regulation of the superoxide 
dismutases of Staphylococcus aureus. Microbiology 2003, 149, 2749–2758. 
112. Bera, A.; Biswas, R.; Herbert, S.; Kulauzovic, E.; Weidenmaier, C.; Peschel, A.; Gotz, F. Influence 
of wall teichoic acid on lysozyme resistance in Staphylococcus aureus. J. Bacteriol. 2007, 189, 
280–283. 
113. Shimada, T.; Park, B.G.; Wolf, A.J.; Brikos, C.; Goodridge, H.S.; Becker, C.A.; Reyes, C.N.;  
Miao, E.A.; Aderem, A.; Gotz, F.; et al. Staphylococcus aureus evades lysozyme-based 
peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. 
Cell Host Microbe 2010, 7, 38–49. 
114. O’Leary, S.; O’Sullivan, M.P.; Keane, J. IL-10 blocks phagosome maturation in mycobacterium 
tuberculosis-infected human macrophages. Am. J. Respir. Cell Mol. Biol. 2011, 45, 172–180. 
115. Bobadilla, K.; Sada, E.; Jaime, M.E.; Gonzalez, Y.; Ramachandra, L.; Rojas, R.E.; Michalak, C.; 
Pedraza-Sanchez, S.; Gonzalez-Noriega, A.; Torres, M. Human phagosome processing of 
mycobacterium tuberculosis antigens is modulated by interferon-gamma and interleukin-10. 
Immunology 2013, 138, 34–46. 
116. Thammavongsa, V.; Kern, J.W.; Missiakas, D.M.; Schneewind, O. Staphylococcus aureus 
synthesizes adenosine to escape host immune responses. J. Exp. Med. 2009, 206, 2417–2427. 
117. Thammavongsa, V.; Missiakas, D.M.; Schneewind, O. Staphylococcus aureus degrades neutrophil 
extracellular traps to promote immune cell death. Science 2013, 342, 863–866. 
118. Panther, E.; Corinti, S.; Idzko, M.; Herouy, Y.; Napp, M.; la Sala, A.; Girolomoni, G.; Norgauer, J. 
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the  
t-cell stimulatory capacity of human dendritic cells. Blood 2003, 101, 3985–3990. 
119. Panther, E.; Idzko, M.; Herouy, Y.; Rheinen, H.; Gebicke-Haerter, P.J.; Mrowietz, U.; Dichmann, S.; 
Norgauer, J. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 
2001, 15, 1963–1970. 
120.  Mascanfroni, I.D.; Takenaka, M.C.; Yeste, A.; Patel, B.; Wu, Y.; Kenison, J.E.; Siddiqui, S.;  
Basso, A.S.; Otterbein, L.E.; Pardoll, D.M.; et al. Metabolic control of type 1 regulatory T cell 
differentiation by ahr and hif1-alpha. Nat. Med. 2015, 21, 638–646. 
121. Koppelman, B.; Neefjes, J.J.; de Vries, J.E.; de Waal Malefyt, R. Interleukin-10 down-regulates 
mhc class ii alphabeta peptide complexes at the plasma membrane of monocytes by affecting 
arrival and recycling. Immunity 1997, 7, 861–871. 
122. Ding, L.; Linsley, P.S.; Huang, L.Y.; Germain, R.N.; Shevach, E.M. IL-10 inhibits macrophage 
costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 
1993, 151, 1224–1234. 
123. De Waal Malefyt, R.; Abrams, J.; Bennett, B.; Figdor, C.G.; de Vries, J.E. Interleukin 10(IL-10) 
inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by 
monocytes. J. Exp. Med. 1991, 174, 1209–1220. 
  
Pathogens 2015, 4 814 
 
 
124. Shibata, Y.; Foster, L.A.; Kurimoto, M.; Okamura, H.; Nakamura, R.M.; Kawajiri, K.; Justice, J.P.; 
van Scott, M.R.; Myrvik, Q.N.; Metzger, W.J. Immunoregulatory roles of IL-10 in innate 
immunity: IL-10 inhibits macrophage production of ifn-gamma-inducing factors but enhances nk 
cell production of ifn-gamma. J. Immunol. 1998, 161, 4283–4288. 
125. Nagamatsu, K.; Kuwae, A.; Konaka, T.; Nagai, S.; Yoshida, S.; Eguchi, M.; Watanabe, M.; 
Mimuro, H.; Koyasu, S.; Abe, A. Bordetella evades the host immune system by inducing IL-10 
through a type iii effector, bopn. J. Exp. Med. 2009, 206, 3073–3088. 
126. Bourgeois-Nicolaos, N.; Lucet, J.C.; Daubie, C.; Benchaba, F.; Rajguru, M.; Ruimy, R.; 
Andremont, A.; Armand-Lefevre, L. Maternal vaginal colonisation by Staphylococcus aureus and 
newborn acquisition at delivery. Paediatr. Perinat Epidemiol. 2010, 24, 488–491. 
127. Shinefield, H.; Black, S.; Fattom, A.; Horwith, G.; Rasgon, S.; Ordonez, J.; Yeoh, H.; Law, D.; 
Robbins, J.B.; Schneerson, R.; et al. Use of a Staphylococcus aureus conjugate vaccine in patients 
receiving hemodialysis. N. Engl. J. Med. 2002, 346, 491–496. 
128. DeJonge, M.; Burchfield, D.; Bloom, B.; Duenas, M.; Walker, W.; Polak, M.; Jung, E.; Millard, D.; 
Schelonka, R.; Eyal, F.; et al. Clinical trial of safety and efficacy of INH-A21 for the prevention 
of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151, 
260–265. 
129. Pauli, N.T.; Kim, H.K.; Falugi, F.; Huang, M.; Dulac, J.; Henry Dunand, C.; Zheng, N.Y.; Kaur, K.; 
Andrews, S.F.; Huang, Y.; et al. Staphylococcus aureus infection induces protein A-mediated 
immune evasion in humans. J. Exp. Med. 2014, 211, 2331–2339. 
130. Bean, A.G.; Freiberg, R.A.; Andrade, S.; Menon, S.; Zlotnik, A. Interleukin 10 protects mice 
against staphylococcal enterotoxin b-induced lethal shock. Infect. Immun. 1993, 61, 4937–4939. 
131. Krakauer, T. Inhibition of toxic shock syndrome toxin-1-induced cytokine production and T cell 
activation by interleukin-10, interleukin-4, and dexamethasone. J. Infect. Dis. 1995, 172, 988–992. 
132. Marlow, G.J.; van Gent, D.; Ferguson, L.R. Why interleukin-10 supplementation does not work in 
Crohn's disease patients. World J. Gastroenterol. 2013, 19, 3931–3941. 
133. Martini, M.; Ciraolo, E.; Gulluni, F.; Hirsch, E. Targeting PI3K in cancer: Any good news? Front. 
Oncol. 2013, 3, 108. 
134. Rafii, S.; Roda, D.; Geuna, E.; Jimenez, B.; Rihawi, K.; Capelan, M.; Yap, T.A.; Molife, L.R.; 
Kaye, S.B.; de Bono, J.S.; et al. Higher risk of infections with PI3K-Akt-mTOR pathway inhibitors 
in patients with advanced solid tumors on phase i clinical trials. Clin. Cancer Res. 2015, 21,  
1869–1876. 
135. Kaymakcalan, M.D.; Je, Y.; Sonpavde, G.; Galsky, M.; Nguyen, P.L.; Heng, D.Y.; Richards, C.J.; 
Choueiri, T.K. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with 
mammalian target of rapamycin inhibitors. Br. J. Cancer 2013, 108, 2478–2484. 
136. Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. 
Cell Biol. 2009, 21, 317–324. 
137. Goldstein, D.M.; Kuglstatter, A.; Lou, Y.; Soth, M.J. Selective p38alpha inhibitors clinically 
evaluated for the treatment of chronic inflammatory disorders. J. Med. Chem. 2010, 53,  
2345–2353. 
138. Genovese, M.C.; Cohen, S.B.; Wofsy, D.; Weinblatt, M.E.; Firestein, G.S.; Brahn, E.; Strand, V.; 
Baker, D.G.; Tong, S.E. A 24-week, randomized, double-blind, placebo-controlled, parallel group 
Pathogens 2015, 4 815 
 
 
study of the efficacy of oral scio-469, a p38 mitogen-activated protein kinase inhibitor, in patients 
with active rheumatoid arthritis. J. Rheumatol. 2011, 38, 846–854. 
139. Cohen, S.B.; Cheng, T.T.; Chindalore, V.; Damjanov, N.; Burgos-Vargas, R.; Delora, P.; Zimany, K.; 
Travers, H.; Caulfield, J.P. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase 
inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid 
arthritis. Arthritis Rheum. 2009, 60, 335–344. 
140. Damjanov, N.; Kauffman, R.S.; Spencer-Green, G.T. Efficacy, pharmacodynamics, and safety of 
vx-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, 
placebo-controlled clinical studies. Arthritis Rheum. 2009, 60, 1232–1241. 
141. Stevens, D.L.; Gibbons, A.E.; Bergstrom, R.; Winn, V. The eagle effect revisited: Efficacy of 
clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 
1988, 158, 23–28. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
